46 Total results for product and free and sample content found
Generics Bulletin
By David Wallace 27 Nov 2020
Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.
Topic Biosimilars Launches Regulation
Datamonitor Healthcare
27 Nov 2020
It is important to understand how the biosimilar market has developed over the past five years. Take a look at some of the key events here.
Topic Biosimilars
Generics Bulletin
By David Wallace 27 Nov 2020
Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.
Topic Biosimilars Regulation
Generics Bulletin
By Akriti Seth 17 Nov 2020
Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.
Topic Coronavirus Biosimilars Deals
Pink Sheet
By Francesca Bruce 21 Sep 2020
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in move towards increasing biosimilar uptake.
Topic EU Biosimilars
Chemist + Druggist Data
By C+D Data 09 Sep 2020
Chemist + Druggist has expanded its “PIP code” system for UK pharmacy procurement to also encompass hospital drugs.
Scrip
06 Feb 2020
For Scrip’s annual preview, our journalists asked over 80 industry executives and experts for their predictions of the major trends for 2020. From AI to M&A, gene therapy to the upcoming US election, here’s what to watch for as we begin this new decade.
Topic Biosimilars BioPharmaceutical
Generics Bulletin
By David Wallace 08 Nov 2019
Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.
Topic Biosimilars Strategy
By Duncan Emerton 04 Nov 2019
If you’re looking at the opportunities to increase revenue and mitigate current and future threats by formulating the strongest biosimilars strategy, Informa’s Biosimilars Insights and Analysis Service is the tool you need.
Topic Biosimilars
No Records Found
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: